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The recent release of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by the
American Psychiatric Association has led to much debate. For this forum article, we asked BMC Medicine Editorial
Board members who are experts in the field of psychiatry to discuss their personal views on how the changes in
DSM-5 might affect clinical practice in their specific areas of psychiatric medicine. This article discusses the influence
the DSM-5 may have on the diagnosis and treatment of autism, trauma-related and stressor-related disorders,
obsessive-compulsive and related disorders, mood disorders (including major depression and bipolar disorders), and
schizophrenia spectrum disorders.
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SchizophreniaIntroduction
The DSM-5 controversy. Tablets from Mount Sinai; a step
backward or the natural progression of advances in
medicine?
Charles B. Nemeroff and Daniel Weinberger
It is unlikely that when the planning for the fifth edition
of the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-5) [1] began 10 years ago, there was any inkling
that the process and the final product would engender such
a remarkable level of criticism, rhetoric, and passion as we
have now witnessed. Any such large undertaking, whether
it is the introduction of a new healthcare plan for a nation,
or the revision of a diagnostic classification of disease, often
does provoke spirited debate, but the criticism of DSM-5
from both within and outside the psychiatric community
has been exceptional. Certainly, no such rancor accom-
panied the release of the 10th edition of the International
Classification of Disease (ICD-10).
When the DSM-5 process was launched several
years ago, the clear hope by all involved was that, fi-
nally, psychiatric diagnoses would include, in
addition to signs and symptoms, various biomarkers* Correspondence: bmcmedicineeditorial@biomedcentral.com
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reproduction in any medium, provided the orof the major disorders including schizophrenia, bipolar
disorder, and major depression, with reasonable measures
of sensitivity and specificity. Because the risk for these dis-
orders has a major genetic component, it seemed plausible
to anticipate including specific genetic markers such as sin-
gle nucleotide polymorphisms or structural genomic ab-
normalities, (for example, copy number variations),
that increase disease vulnerability and perhaps denote
biologically distinct alternative phenotypes. This un-
bridled enthusiasm followed on the heels of the se-
quencing of the human genome and the then-existing
strong belief that many complex diseases in medicine
would be simplified by the results of genome-wide asso-
ciation studies. However, that promise has not been re-
alized in psychiatry, nor in many other branches of
medicine, although historic insights about the genetic
architecture of complex diseases have emerged. Moreover,
our understanding of the underpinnings of the genetic
basis of disease vulnerability and treatment response has
become considerably more sophisticated because of, to
name a few emerging disciplines, epigenetics, non-coding
RNAs, microRNAs, transcriptomics, and proteomics.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of unbridled enthusiasm from brain imaging studies,
both structural and functional, which yielded much
about the neurobiology of the major psychiatric disor-
ders, but without any pathognomonic findings thatDaniel Weinberger is Director and CEO of the Lieber Institute
for Brain Development John Hopkins University School of
Medicine, and Professor of Psychiatry, Neurology, and
Neuroscience at the McKusick-Nathans Institute of Genetic
Medicine. His research interests include the basic neurobiological
and genetic mechanisms of neuropsychiatric disorders,
especially schizophrenia.could be incorporated into DSM-5. In retrospect, none
of this is surprising, as the complexity of brain devel-
opment and of the central nervous system, with its
100 billion neurons that make 500 to 800 billion con-
nections, involves thousands of unique cell types, and
influences behavior as an emergent phenomenon of
interacting genetic programs and complex environmen-
tal experience. The state of the psychiatric diagnostic
manual is, in reality, not much different from that of a
variety of other disorders, ranging from irritable bowel
syndrome, the epilepsies and dystonias, fibromyalgia,
and chronic fatigue syndrome.
The challenge for any effort to revise a phenomenolo-
gically based diagnostic classification scheme is to make
it better, that is, more clinically valuable and more bio-
logically valid. It is doubtful that the current state of the
art of psychiatry research has provided the tools to ac-
complish a major revision. Current enthusiasm for dra-
matic revisions based on dimensional approaches, such
as the research domain criteria (RDoC), endorses the
idea that variation in phenomenological characteristics
of brain function, such as working memory or amygdala
reactivity as measured during a functional magnetic res-
onance imaging (fMRI) protocol, would assign character-
istics to patients that are closer to the underlying
biology of their illness. The implicit assumption is that
treatment would target more specifically these character-
istics, rather than the syndromal classifiers. There is
ample reason to be highly skeptical of this approach, at
least based on the available research data. For example,
patients with attention deficit hyperactivity disorder
(ADHD) and patients with psychosis may show similar
abnormalities of frontal lobe function, just as patients
with post-traumatic stress disorder (PTSD) and patients
with psychosis may show similar overactivation of the
amygdala in fMRI images, but the underlying reasons
for these superficial similarities are different, and so are
the treatments. The treatment for frontal lobe dysfunc-
tion in ADHD (for example, stimulants) will make
psychosis worse, just as the treatment for amygdala
overactivation in psychosis (anti-dopaminergic drugs) is
likely to have adverse effects in patients with PTSD.
In the context of the enthusiasm to revise diagnosis
along the lines of biological rather than clinical phenom-
enology, it is sobering to recall the purpose behind the
historic shift in psychiatric diagnosis represented in
DSM-III. Prior to this, clinical diagnosis was based on
vague, largely implicit assumptions about personality
styles and psychological concepts, such as defense
mechanisms. It was often noted that before DSM-III, the
principal determinant of the diagnosis of a psychiatric
patient was the training program of the psychiatrist.
Clinicians in psychoanalytically oriented programs
would interpret symptoms as indicative of specific
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more biologically oriented program, and the resulting
diagnoses would diverge, often dramatically. DSM-III
introduced explicit criteria that allowed a psychiatrist on
the west coast of the USA to have a much higher likeli-
hood of reaching a similar diagnosis to a colleague on
the east coast. Although the approach was never meant
to establish disease validity, it rescued the field from de-
cades of diagnostic unreliability. It is therefore poten-
tially worrisome that classification using biological
phenomena, such as working memory or amygdala
responsivity, both of which are highly dependent on
context and research protocols, may reintroduce some
of this earlier vagueness, subjectivity, and imprecision.
Much has been made of the apparent overlap of
some genes found to be associated with multiple
psychiatric disorders, but the implications of these
findings for a new diagnostic approach is unclear.
Although the genetics of psychiatric diagnoses may
show some overlap, so do the genetics of multiple
sclerosis and Crohn’s disease, which are distinct clinical
conditions requiring different clinical interventions.
The fact that there may be shared genetic and envi-
ronmental contributors to both major depression and
PTSD, such as early life trauma and FKBP5 polymor-
phisms, should not be surprising, and does not in any
way detract from the utility of these categorical diag-
noses for the practicing physician. Ultimately, a
principle reason for clinical diagnosis is to predict the
course of illness and to prescribe treatment. Current
psychiatric medications are symptomatic treatments
and although many are helpful beyond a single diag-
nosis, there are some dissociations of efficacy that
conform to the existing diagnostic boundaries and ex-
emplify their continuing utility. For example, lithium
is not an effective antipsychotic, but it is nearly cura-
tive for many patients who fulfill the diagnostic cri-
teria for bipolar disorder. Likewise, stimulants tend to
make patients with psychosis worse, but they help
most patients with an ADHD diagnosis. Clozapine, an
especially effective treatment for schizophrenia, is not
effective in autism, intellectual disability, ADHD, or
PTSD.
Although imperfect, and we could be critical of one or
another of the individual changes in DSM-5, it is the
natural and appropriate evolution of the DSM based
on current evidence, from the original classification
system that started with DSM-I in 1952. One
example of a solid improvement is the removal of the
exclusion criterion for bipolar disorder if a patient
‘switched’ into a manic episode after treatment with
an antidepressant. Because there is now overwhelming
evidence that such ‘switches’ occur uniquely in pa-
tients with bipolar disorder and not in those withoutbipolar disorder, that exclusion criterion present in
DSM-IV has now been removed. Similarly, the reloca-
tion of premenstrual dysphoric disorder from the Ap-
pendix to the Mood Disorders section is based on a
decade of research validating this diagnosis.
So why all the controversy? Do the American
Neurological Association or the American Cancer
Society meetings have demonstrators outside their na-
tional meetings protesting their disease classifications?
Do they have those in their ranks refusing to use
their new ICD-10 disease classification? Clearly not.
Was DSM-5 handed down to our field on tablets from
Mount Sinai? Of course not. Were the designers of
DSM-5 intentionally anti-scientific? Of course not.
Will DSM-5 further the field by clarifying categorical
disease classification? Yes.
Overall, is it an improvement over DSM-IV? Yes,
but perhaps not what we all wished for at this stage
in our field.
Will DSM-6 include sensitive and specific diagnostic
tests that are biologically based for schizophrenia, bipo-
lar disorder, and PTSD, to name a few? We all certainly
hope so.Competing interests
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DSM-5 and autism
Michael Rutter
Overall, DSM-5 [1] is disappointing because it failed to
deal with many of the serious challenges in relation to
DSM-IV. There has been a very marginal decrease in the
total number of categories, but the number is still far too
many for any clinician to remember the criteria for each.
The co-occurrence of diagnoses (misleadingly termed
‘co-morbidity’) is likely to remain unacceptably high. No
notice has been taken of the growing evidence of the
lack of distinctiveness between diagnoses. Because the
diagnoses requiring further testing have been placed in
an appendix, this means that their systematic testing
will be impossible (or at least very difficult). It has been
said that as new research findings relevant to classification
become available, these will lead to modifications in the
classification, but who will decide when and how this is
necessary? The desirability of harmonization with ICD-11
has been almost entirely ignored, and it is clear thatMichael Rutter is Professor of Developmental Psychopathology
at the Institute of Psychiatry, Kings College London, and
Consultant Psychiatrist at the Maudsley Hospital, London. He is
founder of the Medical Research Council Child Psychiatry Research
Unit and also the MRC Social, Genetic and Developmental Psychiatry
Centre. His research interests include the genetics of autism, the
development of diagnostic and screening measures for autism,
antisocial behavior, studies of both school and family influences on
children’s behavior, and the interplay between genetic and
psychosocial risk factors.financial considerations have meant that the two major
classifications will remain very different. What has
governed the decisions on changes? It would have been
reasonable to consider clinical utility, but it seems that this
has had a low priority. It could have been scientific validity
but this was examined only in a very partial way with
respect to individual proposals from working groups,
rather than in relation to DSM-5 as a whole.
What about autism spectrum disorders (ASD)? Clearly,
it was necessary to abandon the sub-classification in
DSM-IV, because it had been ignored or sidestepped by
most clinicians and researchers. Despite the plausibility of
the sub-divisions, they had not proven workable, and it
was right to abandon them. Will this lead to a substantial
number of individuals with ASD now failing to meet the
criteria for diagnosis? We do not know, but it is a legitim-
ate concern, especially with high-functioning individuals.
What about the loss of the categories of disintegrative dis-
order and Rett syndrome? The former deals with an un-
common diagnosis of uncertain validity, but the possibility
of testing that has been lost through elimination of the
diagnosis. This removal is in contrast to ICD-11, in which
it is likely that it will be specified as a diagnosis requiring
further testing.
The effects of dropping the coding of Rett’s syndrome
are rather different. Rett’s syndrome has been shown to be
a valid diagnosis and, thus, including it here as a specifier
makes no clinical or scientific sense. The presence of autis-
tic features in an individual with Rett’s syndrome in no way
affects the implications of the diagnosis of Rett’s syndrome,
so why code it? The answer lies in the old-fashioned adher-
ence to a purely descriptive classification, and the absence
of any medical classification in DSM-5.
It should also be noted that the diagnosis of autism is
based solely on two main domains of features, and no
attention is paid to the very common period of transitory
regression, the presence of savant skills, the frequent
increase in head size during the pre-school years, and
the frequent development of epileptic seizures, usually
beginning in later adolescence/early adult life.
Clearly, obliteration of the sub-classification of ASD was
needed because the existing scheme did not work, and
had been ignored by most clinicians and researchers.
However, it is already certain that ASD will prove to be
heterogeneous (clearly so with respect to genetics, but
probably also so with respect to biology). Thus, ASD will
have to be sub-divided again in the future, but how best to
do so remains to be established.
In short, I do not know how DSM-5 will affect the
diagnosis of autism. Probably not very much, but because
DSM-5 will affect access to services, there is a legitimate
concern that some individuals (probably those with higher-
functioning autism) may lose out. What is most obvious is
that DSM-5 has completely ignored the reality of the
Harriet L. MacMillan is Professor in the Departments of
Psychiatry and Behavioural Neurosciences and in the
Department of Pediatrics, Chedoke Health Chair in Child
Studies and Acting Director of Offord Centre for Child Studies
at McMaster University and McMaster Children’s Hospital/
Hamilton Health Sciences. She is a pediatrician and child
psychiatrist, and her research interests include research into family
violence and trials of interventions aimed at prevention of child
maltreatment and intimate partner violence. She is supported by the
Chedoke Health Chair in Child Psychiatry.
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that this phenotype exists, despite the continuing lack of
good criteria for diagnosis. Given the importance of this
phenotype for the possibility of early intervention, this is a
really important opportunity that has been missed. It is
also surprising to see no mention of the pattern of quasi-
autism often seen in patients after profound institutional
deprivation.
Competing interests
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Trauma-related and Stressor-related Disorders
What’s new in DSM-5 for clinicians working with children
exposed to trauma?
Harriet L. MacMillan
As a child psychiatrist and pediatrician practicing in the
area of family violence, I welcome the increased focus on
trauma-related and stressor-related disorders in DSM-5,
which is reflected by several important changes. My hope is
that these changes, as discussed below, will lead to in-
creased recognition and understanding of the impairment
associated with childhood adversities, especially in children.
Ideally, this should occur not only among child psychia-
trists, but among the full range of clinicians engaged in the
assessment and provision of services to children, including
family physicians, nurses, pediatricians, and psychologists.
This aim is consistent with the view of the DSM-5 Task
Force regarding the potential value of the DSM classifica-
tion system to all professionals concerned with mental
health care [1], not just psychiatrists. I am cautiously
optimistic that the DSM-5 will now become more relevant
to those of us seeing children and adolescents with
stressor-related disorders across disciplines.
The key changes for those of us working in the family
violence field are as follows [2]. First, the move of PTSD
and acute stress disorder away from Anxiety Disorders to
a new stand-alone chapter Trauma- and Stressor-Related
Disorders (TSRD), reflects the current deeper understand-
ing of the heterogeneous symptom presentation of stress-
related conditions. In addition, the three major PTSD
symptom clusters in DSM-IV (re-experiencing, avoidance/
numbing, and arousal) have been revised to four clusters:
avoidance/numbing is now divided into the two clusters
of avoidance and persistent negative changes in both
cognition and mood. The latter has been broadened to
include negative emotional states. It is increasingly recog-
nized that PTSD symptoms go beyond fear-based anxiety,
and include dysphoria, aggression, guilt, and shame [3]. Thisis also the case for adjustment disorders, which are now in-
cluded in the same chapter. Another important difference
for the PTSD criteria in DSM-5 is the removal of the sub-
jection reaction (intense fear, helplessness, or horror) of
how an individual experienced a traumatic event.
It is encouraging to see the development of a new PTSD
sub-type in DSM-5: Post-traumatic Stress Disorder for
Children 6 Years and Younger. The DSM-IV PTSD cri-
teria did not take into account the variation in symptom
presentation during development, especially in young
children. For example, the previous requirement for three
avoidance/numbing symptoms in young children, whose
capacities to verbally express such experiences are only
emerging, led to under-recognition of PTSD in children
[4]. The criteria now include one or more symptoms
representing either persistent avoidance or negative altera-
tions in cognitions and mood, and presence of one or
more intrusive symptoms, in addition to two or more
symptoms of alterations in arousal and reactivity.
Richard Bryant is Scientia Professor at School of Psychology,
University of New South Wales. His research interests include
assessment, mechanisms, and treatment of
post-traumatic stress disorder and anxiety. He served on the DSM-5
PTSD/Trauma/Dissociative Work Group and the ICD-11 Working
Party on Stress-related Disorders.
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condition, disinhibited social engagement disorder, in the
TSRD chapter emphasizes the recognition of symptoms
associated with neglect in childhood. In DSM-IV, reactive
attachment disorder had two sub-types, emotionally/
withdrawn and indiscriminately social/disinhibited, but
the latter has now become a distinct disorder, based on
differences in symptom presentation. Typically classifi-
cation of stressor-related disorders in childhood has
emphasized the impairment associated with abuse in
childhood (for example, sexual abuse), rather than neglect.
Both types of symptoms and their association with neglect
are important to recognize.
The effects that such changes in DSM-5 will have on
clinical practice are yet to be determined, but there is
the potential for improved assessment of stressor-related
conditions in children, now that the criteria are more rele-
vant and appropriate. This is essential, both for identifying
stressors such as one or more types of child maltreatment,
which can then potentially be stopped from continuing or
recurring, and for providing evidence-based interventions
to reduce impairment. Increasingly we have approaches
such as trauma-focused cognitive behavior therapy [5,6]
and child–parent psychotherapy [7,8], which have shown
benefits in reduction of PTSD symptoms in children
exposed to sexual abuse and intimate partner violence,
although additional trials are needed to determine the
generalizability of these programs.
Critics of the DSM-5 suggest that lowering the thresh-
old for certain conditions or expanding the symptom
criteria may lead to overdiagnosis, that is, identification
of conditions that do not necessarily need treatment. In
the area of trauma-related and stressor-related disorders,
especially in childhood, the problem has been one of un-
derdiagnosis rather than overdiagnosis. Furthermore, the
need for both a history of exposure and specific trauma
symptoms, as well as association with significant distress
or impairment, reduces the likelihood that overdiagnosis
will occur in this area.
Perhaps the way in which the DSM-5 changes have the
greatest likelihood of improving clinical care for children
with stressor-related conditions is through improvement in
assessment of outcomes in research evaluating the effect-
iveness of interventions. A recent comparative effectiveness
review of interventions addressing child maltreatment [9]
determined that although some programs show promise
in improving child well-being and child welfare benefits,
the evidence is still very limited. One of the limitations
identified in this review was the ‘wide heterogeneity in type
and psychometric soundness of outcome measurement
across studies.’ Possibly the revised classification in DSM-5
will facilitate better outcome measures of stressor-related
conditions that can then be used in ensuring high-quality
evaluations of existing and forthcoming interventions.Competing interests
HLM has no competing interests to declare.Post-traumatic stress disorder in DSM-5
Richard A. Bryant and Simon Wessely
The American Psychiatric Association (APA) recently
launched its latest version of DSM-5 [1] commonly
known as the ‘bible’ of psychiatric disorders in many
countries. One focus of the new edition has been the
restructuring of the diagnostic definition of PTSD. In-
troduced in the 1980 third edition of DSM, and consid-
ered as either an attempt to describe a new syndrome
encompassing the enduring mental-health conse-
quences of war [10], or according to others, as the USA’s
attempt to come to terms with the wider societal trau-
mas of the Vietnam War [11], it has traditionally been
conceptualized as a fear disorder defined by three clus-
ters of symptoms: 1) re-experiencing of fear memories
(for example, intrusive memories), 2) avoidance of
trauma reminders (for example, amnesia, withdrawal,
avoidance of situational reminders), and 3) hyperarousal
symptoms (for example, sleep disturbance, heightened
startle response).
Simon Wessely is Consultant Psychiatrist at King’s College
Hospital and the Maudsley Hospital, and Professor of
Psychological Medicine at Kings College London, and Vice
Dean at Institute of Psychiatry, Kings College London. His
current research interests include clinical epidemiology, psychiatric
injury, and military health. He also served on the ICD-11 Working
Party on Stress related Disorders.
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aimed to expand the definition of PTSD beyond the fear
construct. A primary motivation for this change was the
perception that the term needed to accommodate trauma
survivors who display symptoms of distress but who may
not meet the traditional criteria for PTSD [3]. The ar-
gument was made that war veterans and victims of
crime (to name just two groups of survivors) often
present for clinical assistance with symptoms that are
dominated by anger, guilt, or shame. Accordingly, it
was felt that this should be recognized by adding an
additional cluster of symptoms that formally acknowl-
edged the role of ‘negative alterations in cognition and
mood’, and included the new symptoms of pervasive nega-
tive emotional states, negative appraisals about oneself or
the world, and excessive blame. Some symptoms previously
noted as ‘avoidance’ symptoms (such as withdrawal and
amnesia) were also included in this cluster, because of
much evidence from factor analytic studies that they are
distinct from active avoidance [12]. In total, DSM-5 in-
creased the number of symptoms from 17 in DSM-IV to
20 in DSM-5. To meet the DSM-5 criteria, the individualneeds to have experienced a marked traumatic experi-
ence and satisfy each of the symptoms of re-experience
, avoidance, arousal, and negative alterations in mood
and cognition. The person needs to have impairment,
and the symptoms need to persist for at least 1 month
after the traumatic event.
Do these changes represent a step forward or backward?
In terms of clinical intervention, there is no doubt that the
symptom composition of the new diagnosis may lead to the
diagnosis being applicable to more of those exposed to
trauma. If this were the case, then an increase in prevalence
rates of PTSD would be expected using the DSM-5 criteria
relative to the DSM-IV criteria. In fact, the limited evidence
available suggests that the prevalence rate does not increase
[13], which on one level is a good development because
of the considerable concerns expressed in many quarters
about ‘bracket creep’ with new psychiatric diagnoses;
however, it poses questions concerning the extent to which
the new definition has actually improved identification of
those who have a post-traumatic stress condition. Many
studies attest to people with sub-syndromal PTSD having
comparable levels of impairment to those with full PTSD
[14], emphasizing the conclusion that the arbitrary cut-off
point set by the diagnostic threshold does not perform opti-
mally in classifying those with PTSD-related difficulties.
One consequence of the new definition is that the dis-
order is much more heterogeneous than it was previously
deemed to be. As a result of its multiple cluster format,
PTSD has traditionally been a very heterogeneous dis-
order in DSM, because to satisfy the criteria there must be
a minimum number of symptoms from each cluster: in
DSM-5, at least one of five re-experiencing symptoms,
one of two avoidance symptoms, three of seven cognition
and mood symptoms, and three of six hyperarousal symp-
toms. Considering the various combinations of symptoms
required to meet the definition of the one disorder called
PTSD, it involves a very high number of very distinct pos-
sible combinations. In DSM-IV, this resulted in a total of
79,794 symptom presentations. By adding more symptoms
and an additional cluster, DSM-5 results in 636,120
possible combinations [15]. This is in marked contrast to
the conditions such as Panic Disorder (3), Social Phobia (1),
Obsessive-Compulsive Disorder (3), or Major Depression
(227). A potentially significant consequence of this lack
of homogeneity is that it may represent a significant
obstacle to research that attempts to identify character-
istic markers of the disorder. Although there has been
enormous attention given in recent years to biological
or cognitive markers of PSTD, this research has typically
resulted in mixed findings, lack of replication, or poor
specificity. One strong possibility for the lack of pro-
gress on this front is that the many different clinical
presentations that are encompassed by the PTSD
Dan J. Stein is Professor and Chair of the Dept of Psychiatry
and Mental Health at the University of Cape Town, and
Director of the MRC Unit on Anxiety and Stress Disorders. His
research interests include the psychobiology and management of
the anxiety, obsessive-compulsive and related disorders, and
traumatic and stress disorders. He also served as Chair of the DSM-5
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mechanism or marker.
Although DSM-5 aims to enhance clinical utility, and in
this sense the PTSD diagnosis tries to make it more rele-
vant to those affected by war and crime, future studies will
shed light on whether this has been successful. It is notice-
able that the new proposals for PTSD in ICD-11 have
taken an opposite perspective, and elected to simplify the
diagnosis, while directing clinicians to core features of the
disorder [16]. The increased heterogeneity reflected in
DSM-5 raises serious questions about the utility of the
diagnosis for furthering the research agenda. Given the
many questions that abound concerning the neural,
genetic, cognitive, and behavioral features of the disorder,
we are doubtful that the new definition will facilitate
clarification of these issues.
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Obsessive-compulsive and Related Disorders
DSM-5 and obsessive-compulsive and related disorders
Dan J. Stein
DSM-5 includes a number of changes with respect to
obsessive-compulsive disorder and related conditions
(OCRDs) [1]. First, the chapter on OCRDs is an entirely
new one, and includes obsessive-compulsive disorder
(OCD), body dysmorphic disorder (BDD), and trichotillo-
mania (hair-pulling disorder). Second, the chapter includes
several new conditions, including hoarding disorder and ex-
coriation (skin-picking) disorder. Third, some of the disor-
ders, such as trichotillomania (hair-pulling disorder), have
new names. Fourth, there are a number of new approaches
to the sub-typing of OCRDs. Fifth, there are a number
of changes to the diagnostic criteria of conditions now
classified as OCRDs. Finally, the text relating to OCRDs
has been revised.
These changes were based on a range of scientific data
including those published in the form of a research confer-
ence [17], systematic reviews [18-25], secondary analyses of
existing datasets [26], and DSM-5 field surveys [27-29].
Input was also obtained from members of the OCRD
clinician and research community, consumer advocates,
and the professional and lay public at large [30].
Recommendations made by the DSM Sub-work
Group on Obsessive-Compulsive Spectrum Disorders
were reviewed by a scientific review committee, in somecases by a clinical and public health committee, and
by the DSM-5 taskforce. This piece briefly reviews the
implications for clinical practice.
The new chapter on OCRDs reflects growing data that
OCD differs from the anxiety disorders on a number of
diagnostic validators, and that there are important phe-
nomenological and psychobiological overlaps between
OCD and a number of related conditions [19]. At the
same time, it is important to emphasize that there are
both strong overlaps between OCD and the anxiety disor-
ders, and important differences between the OCRDs. The
close relationship between OCD and the anxiety disorders
is reflected in the order of the chapters in DSM-5, and the
differences between the OCRDs are emphasized in the
DSM-5 text [31].
The potential advantage for clinical practice of a new
chapter is that clinicians and the public will be made
more aware of these underdiagnosed and undertreated
conditions. The hope is that clinicians will screen more
rigorously for these conditions, and that researchers will
use structured diagnostic interviews and standardized
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range of these often-neglected conditions in a systematic
way. A potential disadvantage of having a single chapter
is that some clinicians will fail to appreciate the import-
ant differences that exist between these conditions.
The DSM-5 chapter on OCRDs includes several
new diagnoses, namely hoarding disorder, excoriation
(skin-picking) disorder, substance/medication-induced
OCRD, OCRD due to another medical disorder, and
other specified OCRD. The inclusion of hoarding dis-
order and excoriation disorder reflects a growing
database on the diagnostic validity of these condi-
tions, and the clinical utility of recognizing them in
the nosology [23,32]. The inclusion of substance/
medication-induced OCRD, OCRD due to another
medical disorder, and other specified OCRDs is a lo-
gical consequence of having a separate chapter on
OCRD.
Definitions of psychiatric disorder continue to be
debated, and it is surely important not to medicalize prob-
lems of daily living [33]. However, those who meet diag-
nostic criteria for these conditions experience distress or
impairment, and deserve appropriate intervention. The cat-
egory of other specified OCRD brings attention to those in-
dividuals, who do not meet the diagnostic criteria for a
DSM-5 mental disorder, but who nevertheless experience
clinical distress or impairment; this category includes
individuals with olfactory reference syndrome, obsessional
jealousy, and body-focused repetitive behavioral disorders
other than trichotillomania (hair-pulling disorder) and
excoriation (skin-picking) disorder.
The name ‘trichotillomania’ has been felt by some con-
sumer advocates to be inappropriate and confusing, as
mania is not a defining symptom of this condition. While
some consumer advocates have expressed preference for a
plain language term such as ‘hair-pulling disorder’, others
have felt that such a term would not have sufficient med-
ical gravitas. Furthermore, there would not be continuity
with the previous literature. Thus, the name ‘trichotillo-
mania (hair-pulling disorder)’ was proposed, allowing
individuals the choice of which name to use. A simi-
lar set of considerations led to a proposal for the name
‘excoriation (skin-picking) disorder’.
In DSM-5, OCD, BDD, and hoarding disorder have an
insight specifier that ranges from ‘good insight’ through
‘fair insight’ and on to ‘no insight/delusional’ [34,35]. This
sub-typing reflects the dimensional nature of insight in
OCRDs, the existence of data indicating that different
levels of insight require different treatment approaches,
and a scientific consensus that patients with an OCRD
that reaches delusional levels should be diagnosed with
an OCRD rather than delusional disorder. In DSM-5,
OCD can be specified as tic-related, BDD can be specified
with muscle dysmorphia, and hoarding disorder can bespecified with excessive acquisition, again reflecting the
data that such specifiers have clinical implications
[18,21,22].
Several changes to the diagnostic criteria for
OCRDs have been made. It is notable that some of
these changes help to emphasize the overlapping fea-
tures of conditions in the OCRD chapter. Thus, BDD
includes a new diagnostic criterion, which emphasizes
that individuals respond to their appearance preoccu-
pations with repetitive behaviors or mental state or
acts. Similarly, the criteria for trichotillomania (hair-
pulling disorder) no longer include diagnostic criteria
that conform to the pattern of impulse control disor-
ders, but include an extra criterion, which emphasizes
that individuals have attempted to decrease or stop
the hair-pulling. The validity of such changes have
been confirmed by secondary analyses and field sur-
veys [23,28].
The updated DSM-5 text on OCRDs includes new
information that has emerged since the publication of
DSM-IV, and provides details on key clinical issues
such as prevalence, development, and course, risk and
prognostic factors, culture-related and gender-related
diagnostic issues, suicide risk, and functional conse-
quences. For example, the section on OCD describes
the main obsessive-compulsive symptom dimensions
that have emerged from studies around the world
over the past two decades [36]. Differential diagnosis
of OCRDs is not always straightforward, and the text
may usefully guide clinicians towards a correct
diagnosis.
This brief piece does not allow a comprehensive
discussion of all of the changes made in the DSM-5
chapter on OCRDs. Although any particular change
to the nosology has both pros and cons [37,38], the
rationale for many of the changes is provided in sys-
tematic reviews and proposals published by the
DSM-5 Sub-work Group, which has attempted to
take an evidence-based approach, making changes
that are based on accumulating data on diagnostic
validity and clinical utility. The hope is that such
changes will help clinicians to recognize individuals
with OCRDs, and to diagnose them appropriately.
Such recognition and diagnosis may in turn lead to
better treatments and improved outcomes.
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DSM-5 and depressive disorders: yet more ado about
nothing?
Carmine M. Pariante
Critics have accused the new DSM-5 [1] of multiplying
the number of psychiatric diagnoses and of medicalizing
normal human experience. Two changes in the clinical
area of Depressive Disorders have been used as examples to
support this accusation: the removal of the ‘bereavement
exclusion’, and the introduction of the new Disruptive
Mood Dysregulation disorder (DMDD) for use in children.
In both cases, the accusation is wrong.
The removal of bereavement exclusion will allow indi-
viduals who have been clinically depressed for less than
2 months after the loss of a loved one to be diagnosed
with Major Depression. In the previous (fourth) edition
of the DSM, the diagnosis of major depression could be
made only if the depression had persisted for at least 2
months after the bereavement.
Does this mean that hordes of individuals who have
just lost their partner or their parent will be started on
antidepressants? Obviously not: first, because individuals
will still need to fulfill the diagnostic criteria for depression,
including the impairment in important areas of functioningCarmine M. Pariante is Professor of Biological Psychiatry at
Institute of Psychiatry, Kings College London.
His research focuses on the biological effects of stress, the
pathogenesis of depression, and the molecular mechanisms of
antidepressant drugs.such as in their social or professional life; and second – and
crucially – because no clinically competent doctor would
do so. Two scenarios clarify this.
Scenario 1. A young woman loses her husband in a car
crash. She has no history of psychiatric disorders. She is
grief-stricken and has to take time off work. Because of
the removal of the bereavement exclusion, after 2 weeks,
she clinically fulfills the ‘new’ criteria for major depression, .
She consults her primary care doctor, who reassures her
that she is going through a very difficult process but that
this is normal, and advises her to mobilize the support of
her friends and family and that she will feel better in time.
Scenario 2. A young woman loses her husband in a car
crash. She has had several previous episodes of severe
depression, which have lasted for 1 year or more. During
these previous periods of depression, she has not been
able to hold on to a job, and has tried to commit suicide.
Like the woman in Scenario 1, this woman is grief-stricken,
has to take time off work, and after 2 weeks, clinically
fulfills the ‘new’ criteria for major depression. She sees
her primary care doctor, who is aware of the research
evidence showing the similarities between bereavement-
related depression and other forms of depression [39],
and is therefore rightly concerned that this stressful
event will precipitate yet another severe episode in this
predisposed woman. Until recently, the clinical manage-
ment of such patients within the American health system
would have been influenced by the ‘bereavement exclu-
sion’, which would have complicated the reimbursement
from the medical insurances companies. However, no
longer impinged by this exclusion, the doctor immediately
starts the patient on treatment with an antidepressant that
has proven effective for the patient in the past, and this
prevents the repetition of a downward spiral.
Hence, clinical competency and personalized decisions
are, as always, key to clinical management, and diagnostic
textbooks will not make good doctors take bad decisions.
What about the disruptive mood dysregulation disorder?
Accused of being a diagnosis for ‘grumpy children’, this
disorder requires ‘persistent irritability and frequent
episodes of behavior outbursts, three or more times a
week, for more than a year’ to be present in order to
make the diagnosis. Is this a situation that any sensible
parents (let alone doctors) would call a ‘grumpy child’?
I am sure that many parents would ask for help if they
had a child with such difficulties.
Moreover, the criticism is particularly misplaced
(and ironic) because DSM-5 has introduced this new
disorder to prevent the (ab)use of the diagnosis of bipolar
disorder in children. The rates of bipolar disorder in
children have grown almost six-fold between 1996 and
2004 [40], and this diagnosis is accompanied by the pre-
mature use of antipsychotics and mood stabilizers in very
young individuals, and by a much more stigmatizing
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Elimination of the major depression bereavement
exclusion in DSM-5
Florian Seemüller
Major depression is the worldwide leading cause of
disability in terms of total years lost due to the dis-
ability. Correct diagnosis is a prerequisite for the early
and correct treatment of this disorder. The DSM-5
field trials have shown that the DSM-IV diagnostic
criteria for major depression have a very disappoint-
ing test-retest reliability. Although some diagnoses,
such as PTSD and major neurocognitive disorder had
a very good test-retest reliability (κ values of 0.67 and
0.78), and others such as bipolar I disorder (κ = 0.56),Florian Seemüller is consultant for psychiatry at the
Department of Psychiatry at the Ludwig-Maximilians-University
Munich. His research interests focuses on suicide research, bipolar
disorder, and the systematic, course-related, and clinically oriented
evaluation of longitudinal data from patients with depressive
disorders and disorders among patients with schizophrenia.schizoaffective disorder (κ = 0.50), mild neurocognitive
disorder (κ = 0.48), alcohol use disorder (κ = 0.40) and
binge eating disorder (κ = 0.56) still showed good reliabil-
ity, the test-retest reliability was questionable for condi-
tions such as generalized anxiety disorder (κ = 0.20),
mixed anxiety-depressive disorder (κ = −0.004)
obsessive-compulsive personality disorder κ = 0.31)
antisocial personality disorder (κ = 0.21) and major
depression (κ = 0.28) [41].
Therefore, in order to improve the test-retest reli-
ability and to reduce the number of false positives,
tightening of the diagnostic criteria for such problem
diagnoses would have been desirable; however, with
the elimination of the major depression bereavement
exclusion in the DSM-5 [1], the diagnostic boundaries
have again been widened. Thus, a major depressive
episode can be diagnosed if a person grieves for a
loved one for more than 2 weeks. This challenges the
view that grief after the loss of a loved one, which
frequently comprises depressive symptoms, belongs to
the category of healthy psychic reactions and coping
strategies. This has been the reason why bereavement
has been an exclusion criterion (Criterion E) for the
diagnosis of major depression since DSM-III. The be-
reavement exclusion criterion further specified that a
bereavement-related depressive episode will not be ex-
cluded as major depression and should be diagnosed as
such if it lasts longer than 2 months, or if the patient dis-
plays any one of the several symptoms suggestive of severe
depression, including suicidal ideation and psychomotor re-
tardation. Grief usually resolves in about 80% of all cases
after a couple of weeks or months.
Clinical research further suggests that the risk for recur-
rent depression in people experiencing severe grief is not
different from that of healthy controls [42]. Although some
individuals, especially elderly people with complicated grief,
may benefit from this change, possibly by earlier receipt of
intensive treatment after having lost a loved one, millions
of other people might be unnecessarily labeled as having an
illness, and consequently receive treatment that they do not
need. Because both human and financial resources in men-
tal health care are restricted, such broadening of diagnostic
boundaries always poses the risk that patients with more
severe mental illness who are in need of more and expen-
sive treatments do not receive adequate care. In addition,
this removal of the bereavement exclusion means that
clinicians are not required to distinguish between nor-
mal grief and major depression any longer, and thus it
may mean that this skill will soon disappear from the
clinical training of psychiatry.
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Take (DSM) five: jazzing up the blues?
Michael Berk and Gin S Malhi
A welcome change to the criteria for mania is the em-
phasis on increased activity and energy as well as mood
in Criterion A for manic and hypomanic episodes [1]. This
is concordant with new research on the primacy of energy
clinically, reflecting new data on the role of mitochondrial
energy generation in the disorder, as well as the poor
specificity of ‘irritability’ [43].
The second major change is ‘an addition’ to bipolar
disorder, with broadening of the criteria for mixed states.
It has been correctly argued that DSM-IV did not allow
for the presence of mixed states in bipolar-II disorder,
and convincingly noted that this requirement, which
necessitated the rare occurrence of threshold mania and
depression, was too restrictive [44]. Reviews of more recent
data have supported this view, and led to amendments
in DSM-5 that now allows for mixed mania and mixedGin S Malhi is Head of the Department of Psychiatry, Sydney
Medical School, University of Sydney, and also Director of the
CADE Clinic, Royal North Shore Hospital. His research interests
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novel therapies.depression, which are defined by the simultaneous presence
of three or more features from the opposite pole of the
illness [45]. Some key symptoms that potentially hold
diagnostic significance, such as psychomotor agitation,
have been excluded on the assumption that they occur
in both poles of the illness. Interestingly, discernible
treatment and course effects emerge, along with the
presentation of opposite polarity symptoms with both
depressive and manic episodes, even at relatively low num-
bers (one or two symptoms). Clinically, the latter modest
admixtures of symptoms are remarkably common. How-
ever, the threshold of three symptoms has been criticized
for being potentially too restrictive [46]. Additionally, the
attempt to build a bridge between the constructs of bipolar
mixed states and non-bipolar agitated depression highlights
the spectral nature of the unipolar-bipolar continuum. The
first studies confirming the validity of these criteria have
already appeared [47].
Other significant changes include the incorporation
of criteria for disruptive mood dysregulation disorder
(DMDD), which will influence the field of child psychiatry
[48]. This change has occurred in reaction to discordance
between putative child and adult bipolar populations with
Martin Preisig is Professor at the Department of Psychiatry of
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of the Psychiatric Epidemiology and Psychopathology
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factors, and the growing risk of overdiagnosis of bipolar
disorder in childhood. However, longitudinal studies
suggest that DMDD has poor diagnostic reliability, and
cannot be differentiated adequately from oppositional
defiant disorder and conduct disorder. Furthermore, it
is not associated with current, future-onset, or parental
history of mood or anxiety disorders, confirming the
utility of the revision [49].
Removal of the bereavement exclusion for a depressive
diagnosis is arguably the most contentious ‘loss’ to the
field of mood disorders. Early studies suggested that
after bereavement, depressive syndromes are common
but transient, and do not require treatment. Based on
research studies published since 2006, Zisook and col-
leagues [50] argued persuasively that depression related
to bereavement that occurs in the context of bereavement
is no different phenomenologically from depression in
other contexts, and has similar genetic and familial
patterns, comorbidities, course, outcome, and treatment
response. Hence, the bereavement exclusion was itself
excluded from DSM-5. This has been critiqued [51], and a
number of potential advantages and disadvantages that are
likely to ensue have been identified. The key argument is
that DSM does not meaningfully distinguish between a nor-
mal reaction to loss and the threshold for a disorder, and
that abandoning the bereavement exclusion risks overdiag-
nosis of depression and consequent overtreatment, and in
this regard, the criteria for major depression are arguably
already broad and non-specific. Alternatively, some have
argued for a narrowing of the construct and a return to
the concepts of endogenous and melancholic depression,
suggesting, for example, that greater severity predicts
higher treatment response [52,53].
The changes to the mood disorders taxonomy in
DSM-5 are important because of the widespread in-
fluence of this classification system. As in many other
sections of DSM-5, the underpinning of diagnoses by
neurobiology remains to be achieved, and thus the
diagnoses are largely descriptive and limited by their
dependence on phenomenology and grouping of
symptoms and signs according to clinically defined
cut-offs and associations. Despite these limitations,
the revisions meaningfully incorporate recent advances,
the system has widespread applicability, and alternate
conceptual frameworks such as RDoC do not yet have
overt clinical applicability [54].
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Impact of the DSM-5 on the diagnosis of bipolar and
related disorders
Martin Preisig
The DSM-5 [1] includes the following changes to the
diagnoses of bipolar and related disorders.
First, Criterion A for manic and hypomanic episodes
now requires not only elated, expansive, or irritable mood,
but also abnormally and persistently increased goal-directed
activity or energy. Although activity and energy are highly
relevant features of mania or hypomania, the inclusion of an
additional criterion for mania and hypomania raises
the diagnostic threshold for the diagnoses of bipolar-I
and bipolar-II disorder, and accordingly, it will reduce the
number of patients qualifying for these bipolar diagnoses.
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absolute exclusion criterion for diagnoses of manic or
hypomanic episodes. Indeed, these episodes can now
also be diagnosed when they emerge under antidepres-
sant treatment, and when they persist after cessation of
this medication. This change is very welcome, as it
allows clinicians to also assign the diagnoses of bipolar
disorders to the group of patients who develop manic
or hypomanic episodes under antidepressant treatment
and who otherwise hardly differ from other patients
with bipolar disorder.
Third, the diagnosis of ‘bipolar-I disorder, mixed episode’,
has been removed. Instead, a new specifier, ‘with mixed
features,’ has been added. This specifier applies not only to
manic but also to hypomanic episodes when at least three
depressive symptoms are present, and to major depressive
episodes when at least three manic/hypomanic symptoms
are present but the criteria for mania are not met. This is
also a very necessary change as it considerably lowers the
previous too-high threshold for mixed episodes. However,
disorders involving only major depressive episodes will be
classified within the category of major depressive disorders,
regardless of the presence of mixed episodes, according to
this specifier.
Fourth, DSM-5 introduces a new category of other
specified bipolar and related disorders. The diagnostic
definitions of this category apply to bipolar conditions that
do not meet the requirements for bipolar-I or bipolar-II
disorders. These conditions include 1) hypomanic episodes
of short duration (2 to 3 days) with a history of a major
depressive episode, 2) hypomanic episodes with insufficient
symptoms and a major depressive episode, 3) hypomanic
episodes without prior major depressive episodes, and 4)
short-duration (less than 24 months) cyclothymia. This is a
big step forward with respect to DSM-IV, which did not
include an accurately defined specification of syndromes
below the diagnostic level of bipolar-II, although such syn-
dromes have been shown to occur frequently, and should
be separated from major depressive disorder.
Finally, for both manic/hypomanic and depressive
episodes, a specifier for anxious distress is delineated if
at least two anxiety symptoms are present. This new
specifier adds another feature to characterize mood ep-
isodes more accurately.
In conclusion, the changes to DSM-5 improve the diag-
nostic classification of bipolar disorders. The introduction
of accurate definitions for bipolar conditions below the level
of bipolar-II enlarges the array of accurately defined bipolar
diagnoses, and should increase clinician awareness of these
conditions. Given the currently limited evidence regarding
treatment of these conditions, these more accurate defini-
tions will hopefully lead to increased scientific efforts to
establish the efficiency of such treatments. Similarly, the
more frequent diagnosis of episodes with mixed manicand depressive features that are likely to occur with the
DSM-5 changes should also lead to increased interest in
bipolar disorders with such episodes, which are in general
particularly difficult to treat.
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Schizophrenia Spectrum Disorders
Does DSM-5 facilitate diagnosis of schizophrenia?
Martin Brüne
In May 2013, the APA released the DSM-5 [1], and even
in its nascent state, it has already incited controversy
about its usefulness and appropriateness. In this essay, I
focus on the clinical issues relating to psychotic disorders,
although there are of course other changes made to DSM
that are equally debatable. There is also a need for a more
general discussion about the usefulness of a categorical
classification versus dimensional approaches respecting
the applicability of DSM-5 for scientific purposes [55].
With regard to psychosis, the question as to whether
or not high-risk states should be included in the manual
has been a focus of intense discussion about the pros and
cons of doing so. On the one hand, concern has arisen as
to whether the inclusion of high-risk states may promote
stigmatization of individuals who meet the diagnostic cri-
teria for a high-risk condition, especially in light of findings
suggesting that a transition to psychosis occurs in only
about 20% of cases within the first 6 months, although this
does rise closer to 40% at 3-year follow-up [56]. On the
other hand, it has been argued that such an approach could
actually improve mental health care by encouraging earlier
provision of indicated prevention based on clinical staging,
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with first episodes of psychosis [57]. The inclusion of high-
risk states for psychosis in DSM-5 was eventually dropped,
possibly owing to recent reports suggesting that early inter-
vention such as cognitive therapy does not reduce the tran-
sition rate to psychosis [58], and may at best lead to a delay
of psychosis onset [59].
With regard to the diagnostic criteria for schizophrenia,
changes include the elimination of the special attribution of
bizarre delusions and first-rank auditory hallucinations
according to Schneider's criteria. Because Schneider's
first-rank symptoms were considered non-specific by
the DSM-5 Task Force, and the distinction between
bizarre and non-bizarre delusions vague, two Criterion
A symptoms are now required in DSM-5 for a diagnosis
of schizophrenia. In addition, Criterion A now requires
that a patient must meet at least one of three symptoms
comprising the presence of delusions, hallucinations, and
disorganized speech, which are now regarded as ‘core posi-
tive symptoms’. The traditional sub-typing of schizophrenia
into paranoid, disorganized (hebephrenic), catatonic,
undifferentiated, and residual forms is also now being
discarded altogether, based on the view that sub-types
are diagnostically unstable, unreliable, and invalid. In-
stead, a severity rating of the core symptoms has been
introduced in recognition of the heterogeneity of the
symptomatology.
From a clinician's perspective, it is probably a wise deci-
sion not to assign a diagnostic category to high-risk states
for psychosis. Although improvement of early detection of
early stages of psychosis is still an important mental health
issue, there is little evidence to suggest that the inclusion
of high-risk states in diagnostic systems can contribute to
resolving this clinical imperative. Using a comparison of
psychiatry with other medical domains, this would mean
that a clinician should include sub-threshold raised blood
pressure as a risk factor for hypertension, whereas what
actually helps to detect increased risk for hypertension is
the regular checking of resting state blood pressure [60].
By analogy, regular mental health checks on a much larger
scale than is current in clinical practice may help to dis-
cover not only high-risk states of psychosis [61], but also
early stages of much more common psychiatric conditions
such as depression, anxiety disorder, substance abuse, or
dementia. Classification systems can do little about these
issues, because they are designed, in the first place, for cli-
nicians to reliably diagnose existing, rather than incipient,
conditions of medical (including psychiatric) interest.
With regard to the changes made in DSM-5 respecting
the diagnostic criteria for schizophrenia, these seem, at
first sight, subtle, but may have more profound effects on
how clinicians diagnose and treat patients with schizophre-
nia. Discarding Schneider’s first-rank symptoms as non-
specific breaks with the traditional view that disturbances of‘ego-boundaries’ (in Anglo-American conceptualizations of
psychosis commonly subsumed under the symptomatic
spectrum of delusional beliefs) have ‘core’ diagnostic validity.
This need not be a bad thing, and it would not be justifiable
to keep Schneider’s first-rank symptoms simply based
on historical grounds. However, this paradigmatic shift
reflects inconsistency of the diagnostic validity of schizo-
phrenia symptoms occurring with high-risk symptoms. In
fact, auditory hallucinations in the form of commenting
voices and other first-rank symptoms are ‘core’ to all early
recognition manuals, including the most widely used
Structured Interview for Psychotic Symptoms (SIPS) [62]
or the Comprehensive Assessment of At-Risk Mental States
(CAARMS) [63]. Put another way, how can a clinician
diagnose an at-risk state based on symptoms that are
discarded for the full-blown syndrome?
In a similar vein, dropping the traditional sub-types
of schizophrenia in DSM-5 based on alleged diagnostic
instability over time can be criticized based on evi-
dence from older work suggesting the opposite, espe-
cially when rigorous diagnostic criteria apply [64]. The
lack of evidence with regard to differences between the
sub-types in response to treatment or longitudinal
course is probably based more on a lack of research,
rather than on a genuine lack of differences in these
respects. In fact, it was the explicit goal of the early
protagonists in psychiatry such as Kahlbaum and
Kraepelin to describe clinical ‘entities’ based on symp-
tomatology (which at the time included not just the sub-
jective aspect of symptomatology, but also non-verbal and
paraverbal abnormalities in expression), course and out-
come. This approach has certainly failed, at least to some
degree, yet many clinicians probably share the view that an
insidious early onset of schizophrenia, rapid development
of negative symptoms, poor insight, and behavioral
abnormalities (that is, hebephrenia) is generally associated
with a poorer prognosis respecting recovery, social
functioning, and quality of life, compared with patients
with acute paranoid schizophrenia.
DSM-5 has been designed to assist clinicians in arriving
at reliable diagnoses of psychiatric conditions. Despite the
often heated debate about more or less important detail
questions, it can be conceded that most changes are
minor, with others perhaps being of greater significance.
Some diagnoses have been rearranged and reshuffled into
new categories, such as OCD, for which, interestingly, a
specifier for ‘poor insight’ reflects a dimensional overlap
with delusional disorder. Whether or not DSM-5 will
change clinical practice very much is a matter for critical
evaluation of future prescription practices for both medica-
tion and psychotherapy. Personally, I doubt it will.
Akin to naturally evolving bodies, DSM-5 is a ‘design
compromise’ between clinical and scientific necessities.
It needs to be acknowledged and appreciated that a great
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improve diagnostic accuracy for psychiatric conditions.
However, what the final product of all these endeavors
reflects is that psychiatry has still a long way to go until a
reconciliation of divergent perspectives and attitudes about
human nature and well-being can be accomplished. In
my view, this requires a conceptual integration of the
psychological and behavioral adaptations with which
Homo sapiens is endowed. Such integral perspectives also
include the necessity of reconsidering the utility of standard
biomedical concepts, such as diathesis-stress models for
psychiatric conditions; that is, the evolved biopsychosocial
peculiarities that distinguish psychiatric conditions from
other medical illnesses [65,66].
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Schizophrenia spectrum disorders in DSM-5: In what
directions are the most recent changes taking us?
Paul Lysaker
The DSM-5 [1], as noted in its own appendix, has
made several amendments in its section on Schizophrenia
Spectrum and Other Psychotic Disorders. These amend-
ments include the elimination of the older Kraepelinean
sub-types such as paranoid or disorganized, and the de-
emphasis of bizarre positive symptoms, which previouslyPaul Lysaker is Professor of Clinical Psychology in Clinical
Psychiatry at Indiana University School of Medicine, and Clinical
Psychologist and Clinical Supervisor at the Psychiatric
Rehabilitation and Recovery Center at the Roudebush VA Medical
Center. His research interests include understanding the roots of
psychosocial dysfunction in individuals with schizophrenia, and the
development of new rehabilitative and psychotherapeutically
based interventions.were on their own sufficient for a diagnosis, but now must
be accompanied by at least one other core symptom.
Schizoaffective disorder is now presented as a disorder
defined more longitudinally, and in section 3, which offers
emerging models and measures, a five-point from 0 to 4
scale is presented for clinicians to separately rate the core
disturbances of thought, affect, and behavior. Beyond
these changes, the supporting text on associated features
has been updated to reflect contemporary findings that
have overturned long-standing prejudices. Research is
noted suggesting the incidence of the disorder men and
women is not equivalent as was once widely touted, that
random aggressiveness is uncommon, and that prevalence
rates do vary across cultures and socioeconomic groups.
Although as a whole, the updates appear to match broad
surveys of the literature, the new text is not without some
puzzling areas in which opinions are presented as fact.
We are told that unawareness of illness is equivalent to
anosognosia in neurological disorders and that individuals
with schizophrenia most often require lifelong ‘living
support’ (p. 102) [1]. Arguments exist for both positions,
but each is clearly an area of active debate [67-71], and it
seems important that these conversations should not be
limited with premature claims of consensus.
Of interest in this essay are several questions. Will these
changes significantly affect practice? In what direction are
these changes taking us? What might be the practical con-
sequences of movement in that direction? The response
to the first question seems simple. It appears unlikely the
DSM-5 will have any major effect on practice for patients
with psychosis. The sub-types and importance of symptoms
with bizarre content have not driven current treatment,
and their presence previously was possibly a distrac-
tion that most clinicians probably ignored. The rating
scale presented in section 3 may be useful, just as are
any number of existent scales for assessing the psy-
chopathology of individuals with this condition.
Perhaps a more interesting concern, however, relates
to the direction in which these changes point. Given
what we find now in DSM-5, where are we headed in
the next manual and the one after that? Here it strikes
me that there is movement in DSM-5 towards more
concerted attempts to clearly define the individual com-
ponents of the disorder but not necessarily to discern
how those components are related. It seems possible
that the DSM-5 is pointing to future manuals in which
there will be increasing efforts to make the pieces of
this disorder easier to recognize, but with less concern
for core psychopathological processes such as those
proposed by Bleuler [72], which allow us to make sense
of how schizophrenia spectrum disorders represent a
unique set of disorders.
Although the new DSM seems unlikely to change
practice, further movement towards a more precise
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search and treatment efforts. If these more precisely de-
fined elements of the disorder can become targets of
very specific treatments, or linked with very specific dis-
turbances in cortical function, then this fragmentation is
a cause for optimism. However, given my own reading of
emerging research into the complex biological, psycho-
logical, social, and political factors that interact in
schizophrenia and interrupt the lives of human beings
[73], I hold out little hope for the development of a ‘sil-
ver bullet’ to treat each fragment of the disorder, or for
the discovery of a discrete cause of each fragment. A less
optimistic possibility is that the DSM-5 is pointing toward
a trend in which we are offered precise accounts of the
pieces of schizophrenia that, without an overarching picture
of the disorder, exist functionally as fragments. Others have
raised concerns that psychiatry and the allied mental health
fields are moving back, metaphorically, to a time when
medicine treated the fever rather than the infection. In
essence, I share this worry. Moreover, I am concerned
that if we drift further away from an awareness of the
deeper processes at play, we risk losing touch with his-
tory and consequently risk becoming more arbitrary. An
appreciation of the larger processes possibly at play (for
example, loss of the ability to synthesize and build up
representations of the self and other [73]) not only al-
lows us to see why schizophrenia as a diagnostic cat-
egory makes sense, but also assists us to understand and
respond to some of the human elements of illness and
wellness. It plays a role in keeping alive the view that
patients are not merely objects to treat but unique
beings who have to make sense of and live with their
conditions.
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